MedWatch

Novo Nordisk unsure about chance of reaching upper growth target: "This would require significant changes"

With two months until New Year, Novo Nordisk still does not know whether this year will generate a 5 or 8 percent sales growth. Most likely, it will land somewhere in the middle.

Novo Nordisk Chief Financial Officer Karsten Munk Knudsen | Photo: Novo Nordisk / PR

2020 only has two months left, but the Covid-19 pandemic is generating so much uncertainty Novo Nordisk cannot predict whether it will land on a 5, 6, 7 or 8 percent growth in revenue this year.

The most likely outcome, however, is probably somewhere in the middle, Novo Nordisk's Chief Financial Officer Karsten Munk Knudsen states at a press phone meeting on the occasion of the firm's Q3 report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs